ImmunityBio, Inc. (IBRX) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 5 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for IBRX is $13.50, representing a +77.6% upside from the current price of $7.6. Price targets range from a low of $12.00 to a high of $15.00.
